Loading
Life sciences · Journal article
npj Imaging · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Immunotherapies have revolutionized cancer treatment, yet tools for monitoring immune activation in vivo remain limited. This pilot study investigates the potential of [ 18 F]F-AraG PET to visualize activated T-cell dynamics and to assess the immunomodulatory effects of the STING agonist GSK3745417 ± PD-1 inhibitor dostarlimab. Four patients with advanced solid tumors underwent Baseline [ 18 F]FDG PET/CT, tumor biopsy and [ 18 F]F-AraG PET. GSK3745417 was administered intravenously weekly, with triweekly dostarlimab initiated in Week 2. On-treatment [ 18 F]F-AraG PET scans were acquired at Week 1 and Week 6, accompanied by a biopsy in Week 6. [ 18 F]F-AraG uptake in tumors and organs was quantified using peak tissue-to-plasma ratios. Biopsies were analyzed with imaging mass cytometry, histopathology and multiplex immunohistochemistry (mIHC). Best overall responses were partial response (patient A), stable disease (C/D) and progressive disease (B). Patient A demonstrated the highest Baseline [ 18 F]F-AraG uptake in tumors and stronger increase than other patients at Week 1. Changes in [¹⁸F]F‑AraG uptake from Baseline to Week 6 showed concordance with changes in CD8⁺Ki67⁺TIM3⁻ T‑cell density in the three evaluable patients. mIHC supported the contribution of T-cells to the [ 18 F]F-AraG PET signal. These findings support further clinical application of [ 18 F]F-AraG PET to visualize T-cell dynamics and to assess immunomodulatory effects of (immune)therapies.